(-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis

doi:10.3748/wjg.v13.i8.1162

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 8

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2123)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series.

Item

Count

PDF

291

HTML

1589

Figures (1-7)

243

Sum=2123

Feb 28, 2007 (publication date) through Jul 21, 2024

Times Cited of This Article

Times Cited (74)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Gastric Cancer

World J Gastroenterol. Feb 28, 2007; 13(8): 1162-1169
Published online Feb 28, 2007. doi: 10.3748/wjg.v13.i8.1162

Full Size Figure Download Figure

Figure 5 Inhibitory effects of EGCG on VEGF-induced proliferation of endothelial cells. HUVECs were treated with 20 ng/mL VEGF and EGCG at the indicated concentration and time. EGCG time- and dose-dependently inhibited HUVEC proliferation induced by VEGF. Values are expressed as percent of control (means ± SE, n = 3).

Citation: Zhu BH, Zhan WH, Li ZR, Wang Z, He YL, Peng JS, Cai SR, Ma JP, Zhang CH. (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. World J Gastroenterol 2007; 13(8): 1162-1169
URL: https://www.wjgnet.com/1007-9327/full/v13/i8/1162.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i8.1162